Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Lung cancers with oncogenic mutations in the epidermal growth factor receptor (EGFR) invariably acquire resistance to tyrosine kinase inhibitor (TKI) treatment. Vulnerabilities of EGFR TKI-resistant cancer cells that could be therapeutically exploited are incompletely understood. Here, we describe a...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cell Rep
Huvudupphovsmän: Marcar, Lynnette, Bardhan, Kankana, Gheorghiu, Liliana, Dinkelborg, Patrick, Pfäffle, Heike, Liu, Qi, Wang, Meng, Piotrowska, Zofia, Sequist, Lecia V., Borgmann, Kerstin, Settleman, Jeffrey E., Engelman, Jeffrey A., Hata, Aaron N., Willers, Henning
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624074/
https://ncbi.nlm.nih.gov/pubmed/31216465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2019.05.058
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk